A 58-year-old man presents to the emergency department with acute onset chest pain for 2 hours. He describes the pain as substernal, pressure-like, radiating to the left arm, and associated with diaphoresis. His risk factors include hypertension, diabetes, and smoking. On examination, blood pressure is 135/88 mmHg, heart rate 92 bpm, and respiratory rate 18/min. A 12-lead ECG shows ST-segment depression of 2 mm in leads II, III, aVF, and V4–V6, with T-wave inversion in the same leads. Troponin I measured at 2 hours is 0.08 ng/mL (normal <0.04 ng/mL). What is the most appropriate immediate management strategy?

Explanation

## Diagnosis: NSTEMI with High-Risk Features ### Clinical Presentation The patient presents with classic acute coronary syndrome (ACS) features: - Acute substernal chest pain with radiation to left arm - Associated autonomic symptoms (diaphoresis) - ECG changes: ST-segment depression and T-wave inversion in multiple territories (inferior and anterolateral) - Elevated troponin I confirming myocardial necrosis **Key Point:** ST-segment depression with elevated troponin = NSTEMI (not unstable angina), which requires aggressive dual antiplatelet therapy and anticoagulation. ### Risk Stratification This patient has **high-risk NSTEMI** based on: - Positive troponin (myocardial necrosis confirmed) - Widespread ST-segment depression (≥2 mm in multiple leads) - Dynamic ECG changes - Multiple risk factors (age, diabetes, hypertension, smoking) **High-Yield:** Presence of elevated troponin + ST-segment depression mandates early invasive strategy (coronary angiography within 24 hours per ESC/ACC guidelines). ### Management Algorithm ```mermaid flowchart TD A[Acute chest pain + ECG changes]:::outcome --> B{Troponin elevated?}:::decision B -->|Yes| C[NSTEMI]:::outcome B -->|No| D[Unstable Angina]:::outcome C --> E{Risk stratification}:::decision E -->|High risk| F[Dual antiplatelet therapy]:::action F --> G[Aspirin + P2Y12 inhibitor]:::action G --> H[Anticoagulation: UFH or LMWH]:::action H --> I[Early invasive strategy<br/>Angiography within 24 hrs]:::action E -->|Low risk| J[Conservative strategy<br/>with stress testing]:::action ``` ### Dual Antiplatelet Therapy (DAPT) | Drug | Loading Dose | Mechanism | Advantage | |------|--------------|-----------|----------| | Aspirin | 300 mg | COX inhibition | Rapid onset, irreversible | | Clopidogrel | 600 mg | P2Y12 antagonist | Oral, slower onset | | Ticagrelor | 180 mg | P2Y12 antagonist | Faster onset than clopidogrel | | Prasugrel | 60 mg | P2Y12 antagonist | Potent, faster than clopidogrel | **Clinical Pearl:** In high-risk NSTEMI, ticagrelor or prasugrel are preferred over clopidogrel due to superior outcomes in clinical trials (PLATO, TRITON-TIMI 38). ### Anticoagulation - **Unfractionated heparin (UFH):** 80 U/kg IV bolus, then 18 U/kg/hr infusion (preferred in high-risk patients, renal failure, or if PCI anticipated) - **Enoxaparin:** 1 mg/kg SC BD (alternative, but UFH preferred in high-risk NSTEMI) **Key Point:** Early invasive strategy (angiography within 24 hours) is Class I recommendation for high-risk NSTEMI per ESC 2020 guidelines. ### Why This Answer Is Correct Option 0 combines: 1. Dual antiplatelet therapy (aspirin + clopidogrel) 2. Anticoagulation (UFH preferred in high-risk setting) 3. Early invasive strategy (angiography within 24 hours) This is the gold standard for high-risk NSTEMI and aligns with current ESC/ACC guidelines.